Showing results (121-130 of 209) with videos related to

Sort By:
Pageof 21
American Journal of Infection Control|April 19, 2011
Computer laboratory notification system via short message service to reduce health care delays in management of tuberculosis in TaiwanTun-Chieh Chen, Wei-Ru Lin, Po-Liang Lu, et al.
BMC Pharmacology & Toxicology|December 15, 2017
The clinical efficacy of Afatinib 30 mg daily as starting dose may not be inferior to Afatinib 40 mg daily in patients with stage IV lung Adenocarcinoma harboring exon 19 or exon 21 mutationsChih-Jen Yang, Ming-Ju Tsai, Jen-Yu Hung, et al.
Translational Research : the Journal of Laboratory and Clinical Medicine|May 19, 2010
Antiproliferative effect of Toona sinensis leaf extract on non-small-cell lung cancerChih-Jen Yang, Yu-Jung Huang, Cheng-Yuan Wang, et al.
Scientific Reports|April 8, 2016
Cysteinyl Leukotriene Receptor Antagonists Decrease Cancer Risk in Asthma PatientsMing-Ju Tsai, Ping-Hsun Wu, Chau-Chyun Sheu, et al.
Plos One|July 16, 2015
Erectile Dysfunction in Patients with Sleep Apnea--A Nationwide Population-Based StudyChia-Min Chen, Ming-Ju Tsai, Po-Ju Wei, et al.
Cancer|September 20, 2007
Hormone replacement therapy and lung cancer risk in ChineseKuan-Yu Chen, Chin-Fu Hsiao, Gee-Chen Chang, et al.
Cancers|November 16, 2018
Better Progression-Free Survival in Elderly Patients with Stage IV Lung Adenocarcinoma Harboring Uncommon Epidermal Growth Factor Receptor Mutations Treated with the First-line Tyrosine Kinase InhibitorsMing-Ju Tsai, Jen-Yu Hung, Mei-Hsuan Lee, et al.
Carcinogenesis|August 20, 2013
Lung tumor-associated dendritic cell-derived resistin promoted cancer progression by increasing Wolf-Hirschhorn syndrome candidate 1/Twist pathwayChih-Hsin Kuo, Kuei-Fang Chen, Shah-Hwa Chou, et al.
Oncotargets and Therapy|April 5, 2016
Poorer prognosis in Taiwanese female ever smokers with stage IV lung adenocarcinoma who were readministered a tyrosine kinase inhibitorChih-Jen Yang, Ming-Ju Tsai, Jen-Yu Hung, et al.
BMC Pharmacology & Toxicology|May 11, 2017
The salvage therapy in lung adenocarcinoma initially harbored susceptible EGFR mutation and acquired resistance occurred to the first-line gefitinib and second-line cytotoxic chemotherapyChih-Jen Yang, Jen-Yu Hung, Ming-Ju Tsai, et al.
Pageof 21